Published in Hepatitis Weekly, November 6th, 2006
C. Briani and colleagues, University of Padua, wrote that the study was done "to assess whether pegylated interferon alpha (PEG-IFN alpha) may induce peripheral neuropathy or antibodies to peripheral nerve antigens in patients with hepatitis C virus (HCV) infection."
"We studied 52 patients with HCV (38 men, 14 women; mean age 44.6±10.6 years) treated with IFN alpha. Before therapy (T-0), patients underwent quantitative viral RNA determination, HCV genotype analysis, and neurologic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.